TY - JOUR
T1 - Mefloquine in infants and young children
AU - Luxemburger, Christine
AU - Price, Richard N.
AU - Nosten, Francois
AU - Ter Kuile, Feiko
AU - Chongsuphajaisiddhi, T.
AU - White, Nicholas J.
PY - 1996/12/1
Y1 - 1996/12/1
N2 - In an area where multi-drug resistance in Plasmodium falciparum is a particular problem, more than 500 children under 5 years of age weighing > 5 kg were treated with mefloquine, either alone or combined with an artemisinin derivative, and followed up for a minimum of 28 days. The principal adverse effect was vomiting and this was associated with reduced efficacy of treatment (even when treatment was repeated). Later adverse effects occurred less frequently than in adults. There was no serious toxicity and, in particular, there were no neuropsychiatric side-effects. The high dose of mefloquine (25 mg/kg) required in this area is well tolerated by young children. It should be given in a divided dose of 15 mg/kg initially, followed by 10 mg/kg ≤ 12 hours later.
AB - In an area where multi-drug resistance in Plasmodium falciparum is a particular problem, more than 500 children under 5 years of age weighing > 5 kg were treated with mefloquine, either alone or combined with an artemisinin derivative, and followed up for a minimum of 28 days. The principal adverse effect was vomiting and this was associated with reduced efficacy of treatment (even when treatment was repeated). Later adverse effects occurred less frequently than in adults. There was no serious toxicity and, in particular, there were no neuropsychiatric side-effects. The high dose of mefloquine (25 mg/kg) required in this area is well tolerated by young children. It should be given in a divided dose of 15 mg/kg initially, followed by 10 mg/kg ≤ 12 hours later.
U2 - 10.1080/02724936.1996.11747839
DO - 10.1080/02724936.1996.11747839
M3 - Article
SN - 2046-9047
VL - 16
SP - 281
EP - 286
JO - Paediatrics and International Child Health
JF - Paediatrics and International Child Health
IS - 4
ER -